Skip to content
PatentBrief
Get alertsTop ↑

New Adeno-Associated Virus Capsids for Gene Therapy

This patent describes new types of adeno-associated virus (AAV) capsids and how to use them in cells to deliver genes for therapies or vaccines.

Granted 2022ActiveExpires 2041Owned by University of PennsylvaniaInvented by James M. Wilson, Mauricio R. Alvira, Guangping Gao + 1 more

Original patent title: “Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor”

Plain-English explanation by SahiLast reviewed · October 31, 2026

This patent describes new types of adeno-associated virus (AAV) capsids and how to use them in cells to deliver genes for therapies or vaccines. Granted to University of Pennsylvania in 2022 with 16 claims and 1 forward citation, and it is expected to expire in 2041.

Coverage

What does this patent actually cover?

This patent is about creating specialized tools for gene therapy. It claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → specific versions of adeno-associated virus (AAV) capsids, which are like protective shells for delivering genetic material. Specifically, it describes cultured host cells that contain engineered DNA (recombinant nucleic acid molecules) designed to produce these new AAV capsids, named AAVhu37. These DNA molecules also carry a gene that is not from AAV (a heterologous non-AAV sequence), intended for therapeutic use. The patent details how these engineered cells, when containing specific parts of the AAVhu37 capsid protein sequence (like vp1, vp2, or vp3) and a 'rep gene' (which helps the virus replicate), can be used to produce gene therapy vectors. For example, a cell might be engineered with a plasmid containing the DNA for the AAVhu37 vp1 capsid protein and a therapeutic gene, along with a rep gene from AAV2.

The gap

What does this patent NOT cover?

  • Does not cover AAV capsids that do not use the specific AAVhu37 sequences defined in the claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →.
  • Does not cover the use of these AAV vectors in a living organism, only in cultured host cells.
  • Does not cover the rep gene being from a source other than AAV2 if claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 3, 6, or 9 is considered.
  • Does not cover the recombinant nucleic acid molecule being something other than a plasmid.
  • Does not cover the heterologous non-AAV sequence being identical to an AAV sequence.

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 11357868
StatusActive
FieldBiotech & Medicine
AssigneeUniversity of Pennsylvania
InventorsJames M. Wilson, Mauricio R. Alvira, Guangping Gao and 1 other
Filed2021
Granted2022
Expires2041
Claims16
Times cited1
LitigationNone on record
Value · $176K–$562KModest

What made this novel

The innovation lies in identifying and defining specific novel sequences for AAV capsid proteins (AAVhu37) that can be engineered into vectors for gene delivery. This allows for potentially more targeted or efficient delivery of therapeutic genes compared to previously known AAV types.

The Patent Drawing

Representative patent drawing for Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor (US 11357868)
Representative figure · US 11357868All figures on Google Patents →
Adeno-associated virus (AAV) c…(Primary claim)biotechpharmaceuticalgene editing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

Research laboratories developing gene therapy vectors

02

Biotechnology companies creating new treatments for genetic diseases

Why it matters

The bigger picture

Adeno-associated viruses (AAVs) are crucial for gene therapy because they can deliver genetic material to target cells without causing disease. Developing new AAV variants with improved properties, like better delivery efficiency or reduced immune response, is key to advancing the field. This patent contributes to that effort by providing novel AAV capsid sequences that researchers can use to create more effective gene therapies.

Filed

October 12, 2021

Granted

June 14, 2022

Market context

Who's building on this

Companies in this space

The University of Pennsylvania, through its inventors, is the originator of this technology. Companies in the gene therapy space, such as those focused on rare diseases or neurological disorders, would be the primary entities interested in building upon these novel AAV capsids for their therapeutic development pipelines.

Market impact

This patent, by providing new AAV capsid sequences, aims to expand the toolkit available for gene therapy development. Such innovations are critical for enabling the creation of next-generation therapies that can overcome limitations of existing vectors, potentially leading to new treatments for a wider range of diseases and improving patient outcomes.

Claim 1 — Plain English

What this patent covers

This patent is about creating specialized tools for gene therapy. It claims specific versions of adeno-associated virus (AAV) capsids, which are like protective shells for delivering genetic material. Specifically, it describes cultured host cells that contain engineered DNA (recombinant nucleic acid molecules) designed to produce these new AAV capsids, named AAVhu37. These DNA molecules also carry a gene that is not from AAV (a heterologous non-AAV sequence), intended for therapeutic use. The patent details how these engineered cells, when containing specific parts of the AAVhu37 capsid protein sequence (like vp1, vp2, or vp3) and a 'rep gene' (which helps the virus replicate), can be used to produce gene therapy vectors. For example, a cell might be engineered with a plasmid containing the DNA for the AAVhu37 vp1 capsid protein and a therapeutic gene, along with a rep gene from AAV2.

The clever bit

The innovation lies in identifying and defining specific novel sequences for AAV capsid proteins (AAVhu37) that can be engineered into vectors for gene delivery. This allows for potentially more targeted or efficient delivery of therapeutic genes compared to previously known AAV types.

What it does not cover

  • Does not cover AAV capsids that do not use the specific AAVhu37 sequences defined in the claims.
  • Does not cover the use of these AAV vectors in a living organism, only in cultured host cells.
  • Does not cover the rep gene being from a source other than AAV2 if claim 3, 6, or 9 is considered.
  • Does not cover the recombinant nucleic acid molecule being something other than a plasmid.
  • Does not cover the heterologous non-AAV sequence being identical to an AAV sequence.

Patent timeline

Filing

Application submitted to the patent office

Publication

Application published, typically 18 months after filing

Grant

Patent officially issued

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Moderate

Citation count

6/40

Early citations

Claim breadth

11/20

Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →

Recency

20/20

Granted within 5 years

Assignee scale

20/20

Major company or institution

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Modest

$176K – $562K

Midpoint $351K · 14.9 yr remaining · industry ×3.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

16 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Citations

Patent lineage

Cites earlier patents

41

earlier patents this invention cites as foundations

View prior art →

Cited by later patents

1

later patents that build on this invention

View patents →

Cite this patent

Wilson, J. M., Alvira, M. R., Gao, G., & Vandenberghe, L. H. (2022). New Adeno-Associated Virus Capsids for Gene Therapy (U.S. Patent No. 11,357,868). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/11357868/adeno-associated-virus-aav-clades-sequences-vectors-containing-same-and-uses-the

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US11357868"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:biotech patents →pharmaceutical patents →gene editing patents →

Common Questions

Frequently Asked Questions

What does New Adeno-Associated Virus Capsids for Gene Therapy cover?

This patent describes new types of adeno-associated virus (AAV) capsids and how to use them in cells to deliver genes for therapies or vaccines.

Who owns patent US 11357868?

University of Pennsylvania owns this patent, granted in 2022.

When does this patent expire?

This patent is expected to expire on October 12, 2041, when the invention enters the public domain.

What is patent US 11357868 cited by?

This patent has been cited by 1 later patents that build on its ideas.

What problem does this patent solve?

Adeno-associated viruses (AAVs) are crucial for gene therapy because they can deliver genetic material to target cells without causing disease. Developing new AAV variants with improved properties, like better delivery efficiency or reduced immune response, is key to advancing the field. This patent contributes to that effort by providing novel AAV capsid sequences that researchers can use to create more effective gene therapies.

What does this patent NOT cover?

Does not cover AAV capsids that do not use the specific AAVhu37 sequences defined in the claims.

Same assignee

More from University of Pennsylvania

View all →
US 11499167·2022

Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10

Patent monitoring

Get notified when University of Pennsylvania files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: October 31, 2026 · PatentBrief is not a law firm and this is not legal advice.